Status:
RECRUITING
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Lead Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small c...
Eligibility Criteria
Inclusion
- Voluntarily sign the informed consent and follow the requirements of the protocol.
- No gender limit.
- Age: ≥18 years old and ≤75 years old.
- expected survival time ≥3 months.
- Histologically or cytologically confirmed, unresectable locally advanced or metastatic non-small cell lung cancer.
- Confirmed known HER2-sensitive mutations, investigator-confirmed previous testing results, and trial site laboratory testing results were acceptable.
- Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment.
- Consent to provide archived tumor tissue or fresh tissue samples from primary or metastatic sites within 2 years for biomarker testing; Participants who were unable to provide tumor tissue samples could be enrolled if they met other inclusion and exclusion criteria after evaluation by investigators.
- Must have at least one measurable lesion according to RECIST v1.1 definition.
- ECOG score 0 or 1.
- Toxicity of previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 .
- No severe cardiac dysfunction, left ventricular ejection fraction ≥50%.
- Organ function levels must meet the requirements.
- Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN.
- Urine protein ≤2+ or ≤1000mg/24h.
- For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum/urine pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
Exclusion
- Received chemotherapy, biological therapy, immunotherapy or other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs, etc.).
- Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin.
- Presence of other gene mutations for targeted drug therapy.
- A history of severe cardiovascular and cerebrovascular diseases.
- Active autoimmune or inflammatory diseases.
- Patients with other malignant tumors within 5 years before the first administration.
- Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded.
- Patients with poorly controlled pericardial effusion, pleural effusion, peritoneal effusion, or pelvic effusion with clinical symptoms were judged by the investigator to be ineligible for enrollment.
- Hypertension poorly controlled by antihypertensive drugs (systolic BP \> 150 mmHg or diastolic blood pressure \> 100 mmHg).
- Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases.
- Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastases). .
- Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any ingredient of BL-M07D1.
- Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
- Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \> lower detection limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \> lower detection limit).
- Active infections requiring systemic therapy, such as severe pneumonia, bacteremia, sepsis, etc.
- Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of the last dose).
- Pregnant or lactating women.
- Other circumstances considered by the investigator to be inappropriate for participation in the trial.
Key Trial Info
Start Date :
April 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT06114511
Start Date
April 24 2024
End Date
April 1 2026
Last Update
August 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China